SAN DIEGO, Nov. 4, 2021 /PRNewswire/ -- Viracta
Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company
primarily focused on targeting virus-associated malignancies, today
announced the acceptance of two abstracts for oral presentation and
one for a poster presentation at the upcoming 2021 American Society
of Hematology (ASH) Annual Meeting, which will be held from
December 11-14, 2021, both in
Atlanta, Georgia and
virtually.
"We are thrilled that the final results from our Phase
1b/2 trial in relapsed/refractory EBV
positive lymphoma have been selected for an oral presentation at
ASH, and we are pleased to see our presence expand this year to
include an additional asset from our portfolio," said Ivor Royston, M.D., President and Chief
Executive Officer of Viracta. "Having three abstracts accepted at
ASH is an honor that we believe speaks to the innovative nature of
our growing pipeline. We look forward to the meeting in December
and are excited to share more about these programs following the
presentations."
Details on the abstracts, which have been published on the ASH
website, are shown below:
Nanatinostat (Nstat) and Valganciclovir (VGCV) in
Relapsed/Refractory (R/R) Epstein-Barr Virus-Positive
(EBV+) Lymphomas: Final Results from the Phase
1b/2 VT3996-201 Study (Publication
#623)
Session Name: 624. Hodgkin Lymphomas and T/NK cell
Lymphomas: T/NK Cell Lymphoma Relapsed Therapy
Session Date: Monday, December 13,
2021
Session Time: 10:30 AM - 12:00 PM
ET
Presentation Time: 11:30 AM ET
Presentation Type: Oral
Room: Georgia World Congress Center, Hall A1
Final results from Viracta's Phase 1b/2 trial evaluating Nana-val in R/R
EBV+ lymphoma will be presented. Data from the trial
indicate that Nana-val was well tolerated and showed promising
efficacy.
Enhanced CAR T cell activity with non-covalent BTK/ITK
inhibition (Publication #906)
Session Name: 703. Cellular
Immunotherapies: Basic and Translational IV
Session Date: Monday, December 13,
2021
Session Time: 6:15 PM - 7:45 PM
ET
Presentation Time: 7:30 PM ET
Presentation Type: Oral
Room: Georgia World Congress Center, Hall A1
Data to be featured in the oral presentation relate to
vecabrutinib, a selective, reversible, non-covalent inhibitor of
Burton's tyrosine kinase (BTK) and interleukin-2-inducible kinase
(ITK). These data demonstrate that using vecabrutinib is a novel
strategy to modulate CD19-targeted chimeric antigen receptor (CAR)
T cell functions by increasing their efficacy, and decreasing their
toxicity, while maintaining their proliferative potential.
Efficacy of Vecabrutinib Treatment in a Murine Model of
Sclerodermatous Graft-Versus-Host-Disease (Publication
#1685)
Session Name: 701. Experimental Transplantation:
Basic and Translational: Poster I
Session Date: Saturday, December 11,
2021
Presentation Time: 5:30 – 7:30 PM
ET
Presentation Type: Poster
Location: Georgia World Congress Center, Hall B5
The poster presentation will feature data showing that
vecabrutinib treatment demonstrated efficacy and beneficially
regulated B cell and T cell immune subsets in a preclinical murine
model of sclerodermatous chronic graft-versus-host disease.
Copies of the poster and oral presentations will be available on
the "Events and Webcasts" section of the Viracta website at
https://viracta.investorroom.com/events-and-webcasts following
their presentation at the meeting.
About Nanatinostat
Nanatinostat (VRx-3996) is an orally available histone
deacetylase (HDAC) inhibitor being developed by Viracta.
Nanatinostat is selective for specific isoforms of Class I HDACs,
which is key to inducing viral genes that are epigenetically
silenced in EBV-associated malignancies. Nana-val (nanatinostat and
valganciclovir) is being investigated in multiple subtypes of
relapsed/refractory EBV+ lymphoma and in advanced
EBV+ solid tumors in three ongoing trials, one of which
is a registration-enabling global, multicenter, open-label Phase 2
basket trial in relapsed/refractory EBV+ lymphoma
(NAVAL-1).
About Vecabrutinib
Vecabrutinib is a selective, reversible, non-covalent inhibitor
of Burton's tyrosine kinase (BTK) and interleukin-2-inducible
kinase (ITK). Vecabrutinib is being studied as a potential
enhancer of efficacy and safety of CAR T cell therapy.
About Viracta Therapeutics, Inc.
Viracta is a precision oncology company primarily focused on
targeting virus-associated malignancies. Viracta's proprietary
investigational drug, nanatinostat, is currently being evaluated in
combination with the antiviral agent valganciclovir as an oral
combination therapy in two Phase 2 clinical trials for EBV-positive
(EBV+) lymphoma and one Phase 1b/2 trial in patients with EBV+
nasopharyngeal carcinoma and other EBV+ solid tumors.
Viracta is also pursuing the application of its inducible synthetic
lethality approach in other virus-related cancers.
For additional information please
visit www.viracta.com.
Forward-Looking Statements
This communication contains "forward-looking" statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, without limitation, statements regarding: the
safety and efficacy of Nana-val and vecabrutinib; the significance
of the abstract acceptances; the availability of additional
information in December; and other statements that are not
historical facts. Risks and uncertainties related to Viracta
that may cause actual results to differ materially from those
expressed or implied in any forward-looking statement include, but
are not limited to: Viracta's ability to successfully enroll
patients in and complete its ongoing and planned clinical trials;
Viracta's plans to develop and commercialize its product
candidates, including all oral combinations of nanatinostat and
valganciclovir; the timing of initiation of Viracta's planned
clinical trials; the timing of the availability of data from
Viracta's clinical trials; previous preclinical and clinical
results may not be predictive of future clinical results; the
timing of any planned investigational new drug application or new
drug application; Viracta's plans to research, develop and
commercialize its current and future product candidates; the
clinical utility, potential benefits and market acceptance of
Viracta's product candidates; Viracta's ability to manufacture or
supplying nanatinostat, valganciclovir and pembrolizumab for
clinical testing; Viracta's ability to identify additional products
or product candidates with significant commercial potential;
developments and projections relating to Viracta's competitors and
its industry; the impact of government laws and regulations;
Viracta's ability to protect its intellectual property position;
and Viracta's estimates regarding future expenses, capital
requirements and need for additional financing in the future.
These risks and uncertainties may be amplified by the COVID-19
pandemic, which has caused significant economic uncertainty. If any
of these risks materialize or underlying assumptions prove
incorrect, actual results could differ materially from the results
implied by these forward-looking statements. Additional risks and
uncertainties that could cause actual outcomes and results to
differ materially from those contemplated by the forward-looking
statements are included under the caption "Risk Factors" and
elsewhere in Viracta's reports and other documents that Viracta has
filed, or will file, with the SEC from time to time and available
at www.sec.gov.
The forward-looking statements included in this communication
are made only as of the date hereof. Viracta assumes no obligation
and does not intend to update these forward-looking statements,
except as required by law or applicable regulation.
Investor Relations Contact:
Ashleigh Barreto
Head of Investor Relations & Corporate Communication
Viracta Therapeutics, Inc.
abarreto@viracta.com
SOURCE Viracta Therapeutics, Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/viracta-therapeutics-announces-upcoming-oral-and-poster-presentations-at-the-2021-american-society-of-hematology-annual-meeting-301416536.html
SOURCE Viracta Therapeutics, Inc.